Tech Company Financing Transactions
Synta Pharmaceuticals Funding Round
Duquesne Capital Management and Gollust Management participated in a $50 million Series C venture round for Synta Pharmaceuticals. This venture round was announced on 1/14/2004.
Transaction Overview
Company Name
Announced On
1/14/2004
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Gollust Management (Keith Gollust)
Proceeds Purpose
This financing enables Synta to accelerate the development of its three lead clinical programs in cancer and autoimmune disease, while maintaining investment in its promising earlier-stage product candidates.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Barr Harbor Dr. 400
West Conshohocken, PA 19428
USA
West Conshohocken, PA 19428
USA
Phone
Undisclosed
Website
Email Address
Overview
Synta Pharmaceuticals (Nasdaq: SNTA) is a pharmaceutical company focused on discovering, developing, and commercializing breakthrough products for severe medical conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Friedman
Chief Financial Officer
Marc Schneebaum
Chief Medical Officer
Rebecca Taub
Browse more venture capital transactions:
Prev: 1/14/2004: Actimize venture capital transaction
Next: 1/15/2004: BenefitPoint venture capital transaction
Share this article
Where The Data Comes From
We do our best to document funding rounds that are announced publicly. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs